Genetic Architecture of Circulating Very-Long-Chain (C24:0 and C22:0) Ceramide Concentrations
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Total ceramide concentrations are linked with increased insulin resistance and cardiac dysfunction. However, recent studies have demonstrated that plasma concentrations of specific very-long-chain fatty ceramides (C24:0 and C22:0) are associated with a reduced incidence of coronary heart disease and all-cause mortality. We hypothesized that specific genetic loci are associated with plasma C22:0 and C24:0 concentrations. Methods: Heritability and genome-wide association studies of plasma C24:0 and C22:0 ceramide concentrations were performed among 2,217 participants in the Framingham Heart Study Offspring Cohort, adjusting for cardiovascular risk factor covariates and cardiovascular drug treatment. Results: The multivariable-adjusted heritability for C22:0 and C24:0 ceramides was 0.42 (standard error [SE], 0.07; p=1.8E-9) and 0.25 (SE, 0.08; p=0.00025), respectively. Nineteen single nucleotide polymorphisms (SNPs), all on chromosome 20, significantly associated with C22:0 concentrations; the closest gene to these variants was SPTLC3. The lead SNP (rs4814175) significantly associated with 3% lower plasma C22:0 concentrations (p=2.83E-11). Nine SNPs, all on chromosome 20 and close to SPTLC3, were significantly associated with C24:0 ceramide concentrations. All 9 were also significantly related to plasma C22:0 levels. The lead SNP (rs168622) was significantly associated with 10% lower plasma C24:0 ceramide concentrations (p=9.94E-09). Conclusion: SNPs near the SPTLC3 gene, which encodes serine palmitoyltransferase long chain base subunit 3 (SPTLC3; part of the enzyme that catalyzes the rate-limiting step of de novo sphingolipid synthesis) were associated with plasma C22:0 and C24:0 ceramide concentrations. These results are biologically plausible and suggest that SPTLC3 may be a potential therapeutic target for C24:0 and C22:0 ceramide modulation.
Abstract
Objective: Total ceramide concentrations are linked with increased insulin resistance and cardiac dysfunction. However, recent studies have demonstrated that plasma concentrations of specific very-long-chain fatty ceramides (C24:0 and C22:0) are associated with a reduced incidence of coronary heart disease and all-cause mortality. We hypothesized that specific genetic loci are associated with plasma C22:0 and C24:0 concentrations. Methods: Heritability and genome-wide association studies of plasma C24:0 and C22:0 ceramide concentrations were performed among 2,217 participants in the Framingham Heart Study Offspring Cohort, adjusting for cardiovascular risk factor covariates and cardiovascular drug treatment. Results: The multivariable-adjusted heritability for C22:0 and C24:0 ceramides was 0.42 (standard error [SE], 0.07; p=1.8E-9) and 0.25 (SE, 0.08; p=0.00025), respectively. Nineteen single nucleotide polymorphisms (SNPs), all on chromosome 20, significantly associated with C22:0 concentrations; the closest gene to these variants was SPTLC3. The lead SNP (rs4814175) significantly associated with 3% lower plasma C22:0 concentrations (p=2.83E-11). Nine SNPs, all on chromosome 20 and close to SPTLC3, were significantly associated with C24:0 ceramide concentrations. All 9 were also significantly related to plasma C22:0 levels. The lead SNP (rs168622) was significantly associated with 10% lower plasma C24:0 ceramide concentrations (p=9.94E-09). Conclusion: SNPs near the SPTLC3 gene, which encodes serine palmitoyltransferase long chain base subunit 3 (SPTLC3; part of the enzyme that catalyzes the rate-limiting step of de novo sphingolipid synthesis) were associated with plasma C22:0 and C24:0 ceramide concentrations. These results are biologically plausible and suggest that SPTLC3 may be a potential therapeutic target for C24:0 and C22:0 ceramide modulation.
참고문헌 (27)
- Holland WL, "Lipid mediators of insulin resistance", Nutr Rev, 65, pp.S39~S46 (2007)
- Ussher JR, "Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption", Diabetes, 59, pp.2453~2464 (2010)
- Chiu HC, "A novel mouse model of lipotoxic cardiomyopathy", J Clin Invest, 107, pp.813~822 (2001)
- Park TS, "Ceramide is a cardiotoxin in lipotoxic cardiomyopathy", J Lipid Res, 49, pp.2101~2112 (2008)
- Chokshi A, "Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure", Circulation, 125, pp.2844~2853 (2012)
- Peterson LR, "Ceramide remodeling and risk of cardiovascular events and mortality", J Am Heart Assoc, 7, pp.e007931~ (2018)
- Laaksonen R, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol", Eur Heart J, 37, pp.1967~1976 (2016)
- Tarasov K, "Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency", J Clin Endocrinol Metab, 99, pp.E45~ (2014)
- Brice SE, "Sphingolipids and metabolic diseases", pp.2011, Landes Bioscience
- Feinleib M, "The Framingham Offspring Study. Design and preliminary data", Prev Med, 4, pp.518~525 (1975)
- Jiang H, "Development and validation of LC-MS", MS method for determination of very long acyl chain(C22 : 0 and C24 : 0)ceramides in human plasma, 2013, pp.405, 7357~7365
- Chen MH, "RVFam : an R package for rare variant association analysis with family data", Bioinformatics, 32, pp.624~626 (2016)
- de Mello VD, "Link between plasma ceramides, inflammation and insulin resistance : association with serum IL-6 concentration in patients with coronary heart disease", Diabetologia, 52, pp.2612~2615 (2009)
- Zhou YT, "Lipotoxic heart disease in obese rats : implications for human obesity", Proc Natl Acad Sci U S A, 97, pp.1784~1789 (2000)
- Yu J, "Ceramide is upregulated and associated with mortality in patients with chronic heart failure", Can J Cardiol, 31, pp.357~363 (2015)
- Russo SB, "Myristate-derived d16 : 0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties", J Biol Chem, 288, pp.13397~13409 (2013)
- Lopez X, "Plasma ceramides are elevated in female children and adolescents with type 2 diabetes", J Pediatr Endocrinol Metab, 26, pp.995~998 (2013)
- Haus JM, "Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance", Diabetes, 58, pp.337~343 (2009)
- Illig T, "A genome-wide perspective of genetic variation in human metabolism", Nat Genet, 42, pp.137~141 (2010)
- Mirkov S, "SNPs affecting serum metabolomic traits may regulate gene transcription and lipid accumulation in the liver", Metabolism, 61, pp.1523~1527 (2012)
- Ogretmen B, "Sphingolipid metabolism in cancer signalling and therapy", Nat Rev Cancer, 18, pp.33~50 (2018)
- Morad SA, "Ceramide-orchestrated signalling in cancer cells", Nat Rev Cancer, 13, pp.51~65 (2013)
- Sassa T, "A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells", Biochim Biophys Acta, 1821, pp.1031~1037 (2012)
- Park JW, "Ceramide synthases as potential targets for therapeutic intervention in human diseases", Biochim Biophys Acta, 1841, pp.671~681 (2014)
- Stiban J, "Very long chain ceramides interfere with C16-ceramide-induced channel formation : a plausible mechanism for regulating the initiation of intrinsic apoptosis", Biochim Biophys Acta, 1848, pp.561~567 (2015)
- Hicks AA, "Genetic determinants of circulating sphingolipid concentrations in European populations", PLoS Genet, 5, pp.e1000672~ (2009)
- Lemaitre RN, "Genetic loci associated with circulating levels of very long-chain saturated fatty acids", J Lipid Res, 56, pp.176~184 (2015)